ArticleMicrobiology spectrum2026
Long-term effects of reovirus strain T3D on the myocardium.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antiviral innate immunity in myocarditis: mechanisms and emerging therapeutics.Experimental & molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Mammalian orthoreovirus (reovirus) is a well-established model for studying viral pathogenesis. Although studies of reovirus have largely been focused on central nervous system disease, reoviruses can also cause myocarditis. Reovirus strain type 1 Lang (T1L) causes mild myocarditis in neonatal mice. However, many highly myocarditic reoviruses are reassortants between T1L and the serotype 3 (T3) Dearing strain that is non-myocarditic. Although cardiac immune responses to T1L are well described, many open questions remain regarding cardiac immune responses to T3 reoviruses. To better understand the effects of T3 reoviruses on the heart, we investigated the long-term cardiac impact of reovirus strain T3 Dearing (T3D) in neonatal C57BL/6 mice. Oral infection with T3D resulted in subclinical myocarditis that was non-lethal but still produced persistent histological myocardial alterations. Echocardiographic analysis revealed a mild decrease in diastolic left ventricular anterior wall thickness in mice infected with 10⁴ PFU, though no consistent dose-dependent functional impairments were observed. Histological examination identified myocardial lesions characterized as replacement fibrosis that developed independently of the inoculating dose. Flow cytometry showed an early immune response at 8 days post-infection, with increased CD4 T cells, CD8 T cells, B cells, and innate immune cells. By 26 days post-infection, the inflammation had largely resolved, but low-level immune infiltration persisted, characterized by CD4 T cells, CD8 T cells, and B cells. These findings suggest that T3D induces subclinical myocarditis with lasting histopathological changes. The presence of fibrosis raises concerns about potential long-term cardiac effects, emphasizing the need for further research into the myocardial impact of non-myocarditic reoviruses.IMPORTANCEViral infections that cause myocarditis are a significant cause of morbidity and mortality worldwide, particularly in children and young adults. Mammalian orthoreoviruses (reoviruses) are an established model for studying viral myocarditis in mice and are also under development as a cancer therapeutic due to their capacity to kill cancer cells. Here, we describe the long-term myocardial effects of the type 3 Dearing (T3D) reovirus strain, which is classically considered neurotropic. Our findings indicate that T3D causes subclinical myocarditis that is non-lethal but produces histopathological changes indicative of fibrosis. Thus, although T3D does not cause overt acute cardiac pathology, it can have long-term effects on the myocardium. This work will inform future studies on reovirus tropism and is relevant to ongoing efforts to harness the oncolytic properties of reoviruses for therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.